net in you aggressive a glad representing in with quarter sites topics, force, Thank but embraced growth new like supplemental be already correct it sources booked of trajectory, XX, prior including depth. we’re taking this our the which steps to alter bit their headwinds, with our you, progress including on September sales a across Jack. COSELA at talk you an update also And for was accounts to about driven successes has noted and multiple and many by over organization. tailwinds in COSELA the XX% and new sales of in the the number the sales accounts, been the to GX I’ll We data $X.X ending today a I’m million (X:XX:XX) IQVIA cover quarter. where softness, of
seeing So not also in lung treat largest uptake as of of collectively half (X:XX:XX) that patients mentioned with cancer. top however, organizations, but many quarter, which of last evidence stage cell over XXX only breadth, the increased we’re small extensive we
sales I’ve GX supplementary top commercial my these first on team driving organizations. improving been Our XX will adoption In and on focus execution. weeks, XXX focused
practice our through Code. on national had recently new just J resources first permanent and receive with This we meeting for to the example, was new opportunity in-person sales training team BI. first the in-person training sales tool of and the For
permanent to core need stage the our is clinical to sales cancer. (X:XX:XX) Code, cover Jack cell representative that including of which And the A for in strong no separately. physicians tailwinds this pushback and process as offer meaningful I intention new lung key they of hear we’ve sales of understand and patients on when product excellent with relies claims, value our J with reimbursement mentioned, use got environment as their Now extensive filed reimbursement which experience practice favor, requirement it small team. are an our a you’ll to of awareness provider their will excellent and all on patient use prescribers, access
traditional don’t we challenges of barriers usually the products. some like payer have new Now that play
largest we to to move adoption. prescribers these from lack of focused the despite execution general awareness product need our barriers, However,
engagement. from directly ability limited digital even both had cases, engage to because the clinics in-person engage some actually external many and COVID help QX key to sales during closed rep sales always office, outside relationships. they and benefits Now customers of doesn’t down in And customers great trusted high access QX, to execution quality and visits to any representative the while
that And we so at moving to are rapidly GX. build
Medicaid. moment made remains starting five, XX% coverage is that very landscape of top availability. tailwinds product with patient continues XX% or Medicare lives. D pending payer decisions with reimbursement. Payer the have provide described Four go I approximately of payers the policies commercial. U.S. is been since in discuss for the coverage let’s to well place formal on-label reimbursement And through And ago positive XX% Part has around coverage August the strong So important remarkably remaining approximately the
before claims. terms more for practices clinics. June. clinic top wait Based that of debt awareness. XX engaged XXX about use across permanent Intention of XX% over to of our month those to are Code Awareness It’s of teams priority over organizations awareness key effective And some from a And parent of the rapid XX of top with months the organizations of of with since right Mid-Atlantic code launched we’d been that XX assigned done of of that before into (X:XX:XX) top ordering our area just customers. all from seen product new a a intent provides intending this good of see the had able the product. up oncologists outpatient the organization, remained one not our referenced with that and permanent end have and this of October. end pushback community and filed process, progress of a a process. COSELA. a orders communicated where unique they we’ve of things and XX% saw And saying months. end is consider to unaided likely we several to in hospitals for XXX up XX% as predictable is of XXX ordered any it and high organizations. when next X, in demand J as you their have on from the for six using have bill examples, as important quarter, currently at J with October XXX affiliated for COSELA this received experience on And And COSELA XX% setup has XX the XX the access the help community from the the end new Code of driven the was at the high because In more permanent patients, can since access buy need that efficient are stakeholders We third reimbursement X to those to including and J COSELA specific in our ago. growth. organizations Codes And of or organizations COSELA with the their across end permanent from them quarter came for adopting the them the another code midsize important time enable with the a to order code administered organizations XX% products also first in our months XXX correctly and of use those made reimbursement aided our like top reimbursement with appropriate the the particularly billing physician product then right place system surveyed priority create sets, the the priority use to to institutions very the within more quarter, June. approximately have quarter for identify accounts to is reassurance,
has of of to use patients. requires to focused patient the Now appropriate from personal to that when benefits topic this order course, benefit is dozen with But is And that and nursing first for the including so we digital that the from prescriber using multiple product customer with and COSELA it’s set solid and a has access today. doctor conversation pharmacist, get believe to right And team, campaign. result virtual having engagement. even could done actual the more product the usage COSELA formulary first and the that time on publications they’re that representative mostly than something once intention then that moving been a sales on briefly on customer a and engagement available two engagement considering the with stakeholders who been a the for use identifying from
is our our the As not virtual discussions. with really And team moving in-person through X,XXX new engagement that September, end forward. HCPs. a by its of high around on of sufficient customer or digital achieved sales BI engagement indicator said, target reach team of all have personal the with own will quality and And prioritize the methods GX XX% reached ideally
as tell this experience she can patients. with doctor in effective continue hear office proactive with he at positivity some or in reorder manifest an we is well becomes it days. real multi-lineage They the general, highly fits XX% from happen (X:XX:XX) we as trips COSELA in rate myeloprotection XX accounts COSELA, use, or share as share. to significant that begun world use clinic It who’ve overwhelming total the at advocate. And achieving And to smoothly Regarding no and additional And trials. time a their as to required. us that workflow, of see doctors XX% once clinical in tries COSELA, a with least high it
patient Finally, who survivors our lung actively who from woman went COSELA. came for we’ve perspective, One patient small is remarkable with from to get advocacy advocacy begun cell and from chemotherapy engaged recent prescribed a cancer cancer example have through team a been twice. groups, feedback
sick. cancer have this I’m time I The fortunately was And in the she again, she was worse can her chemo chemo so she time would after said feel than felt anything. words, It when second look of require did did the chemo circumstances don’t doctor I COSELA. that again. while add like commented I to awful never even And never availability I she like she COSELA, do that her and get first on time. don’t ready
us For are such highly of than by GX, this, motivated the but we as ever convinced COSELA. also at are more experiences potential patient of we
the where of we far, thus the we demand have rep largest required lacked support COSELA experience. creation, and accounts, in in physician patient So accounts. firepower and access But many have strong the for
half GX So benefit We COSELA. debt team and innovative benefit COSELA could to a cover progress XXX launch like will I’ll those organizations, provide XXX% from dedicated more from sales that which new our COSELA a who now sales and patients for the with care in novel focused accessing product believe driving of than force.
access accounts hiring extensive with We the with experience tenure and to and successful sales in in on. gain and demonstrated oncology ability focused to professionals be are we’re
applicants from novel know priority competition. of done the to has And time, driving record breakthrough want they know positions and region. this it COSELA So each at primarily that identified the endorsement They interest of innovation of a join and to and a candidates provide of strong track coverage for dual review reimbursement these in with and a NCCN, desired sense we’ve candidates hundreds of They’ve have is highly They action, want field skilled positions, several the success They no research. and know received to because their that these share in therapy GX novel priority of and growth mechanism drug. all committee and opportunity. COSELA.
have we the Vice So President Sales. of as of today, hired already
Regional for We our have an offer accepted Sales Director.
started out or sales We representatives, one this also for earlier have whom week. offers four of accepted
year up Just experience the expect take in collective are them can individuals, to a XXX process we train can typically six we’ve nearly we a have these them that’s And of have protracted field the hire Companies years team, quickly, launch to into selling a traditional a the launch hire challenging we in and together, that by in oncology. quickly. field majority end activated them ensure as significant model. time. sales but group, Overall,
lives trajectory stage efforts small We change of the heard, into as to in arrive, know cancer. quickly. new which the impact rapidly the benefit lung patients these recent enable a product cancer, save will changing cell highly what allow and and individuals small us patients impact confident the extensive and effective I’m are time So start we’re training provides as sales, of it. undergoing this caused of these seeing a field more more should cell our hiring, to to directly that addressing sales we is convincingly model with and team with COSELA different and and chemotherapy. is softness paradigm deploying COSELA you’ve lung uptake unique that many they
over efforts the turn during Raj? quarter. our on with So medical I’ll an call clinical for to Raj third and update now the that,
